- Home
- Publications
- Publication Search
- Publication Details
Title
Imaging endpoints for clinical trial use: a RECIST perspective
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 10, Issue 11, Pages e005092
Publisher
BMJ
Online
2022-11-25
DOI
10.1136/jitc-2022-005092
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis
- (2022) Laurent Dercle et al. JAMA Oncology
- Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0
- (2022) E. Lopci et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Progression-free survival: it is time for a new name
- (2022) Bishal Gyawali et al. LANCET ONCOLOGY
- iRECIST and atypical patterns of response to immuno-oncology drugs
- (2022) Jorge Luis Ramon-Patino et al. Journal for ImmunoTherapy of Cancer
- Characteristics of available studies and dissemination of research using major clinical data sharing platforms
- (2021) Enrique Vazquez et al. Clinical Trials
- CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody
- (2021) Michael D. Farwell et al. JOURNAL OF NUCLEAR MEDICINE
- 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer
- (2021) I.C. Kok et al. ANNALS OF ONCOLOGY
- Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
- (2021) Egesta Lopci Journal of Clinical Medicine
- Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
- (2020) Flora Mulkey et al. Journal for ImmunoTherapy of Cancer
- Enhanced detection of treatment effects on metastatic colorectal cancer with volumetric CT measurements for tumor burden growth rate evaluation
- (2020) Michael L. Maitland et al. CLINICAL CANCER RESEARCH
- The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
- (2020) Quentin Lecocq et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
- (2019) Lucas Goldfarb et al. EJNMMI Research
- RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis
- (2019) Saskia Litière et al. JOURNAL OF CLINICAL ONCOLOGY
- Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2018) D A Eichenauer et al. ANNALS OF ONCOLOGY
- FDG PET/CT for assessing tumour response to immunotherapy
- (2018) Nicolas Aide et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- F-18 FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma
- (2018) Kimiteru Ito et al. JOURNAL OF NUCLEAR MEDICINE
- 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
- (2018) Frederike Bensch et al. NATURE MEDICINE
- Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
- (2017) Hoda Anwar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18 F-FDG PET/CT Imaging in Patients with Advanced Melanoma
- (2017) Steve Y. Cho et al. JOURNAL OF NUCLEAR MEDICINE
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- 1070PADAPTATION OF THE IMMUNE RELATED RESPONSE CRITERIA: IRRECIST
- (2017) O. Bohnsack et al. ANNALS OF ONCOLOGY
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- RECIST — learning from the past to build the future
- (2016) Saskia Litière et al. Nature Reviews Clinical Oncology
- Response assessment criteria for brain metastases: proposal from the RANO group
- (2015) Nancy U Lin et al. LANCET ONCOLOGY
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
- (2014) Ronald Boellaard et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
- (2013) M. Nishino et al. CLINICAL CANCER RESEARCH
- Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes
- (2011) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- Validation of novel imaging methodologies for use as cancer clinical trial end-points
- (2008) D.J. Sargent et al. EUROPEAN JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started